CHMP declares atypical femur stress fractures a bisphosphonate class effect
This article was originally published in Scrip
Executive Summary
Experts on the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) have concluded that rare atypical fractures of the femur are a class effect of bisphosphonates but that they should be retained to treat and prevent bone disorders. While the CHMP confirmed the benefits of bisphosphonates it recommends that a warning of the fracture risk be added to the prescribing information for all medicines containing bisphosphonates in the European Union.